SLC37A4: A Potential Drug Target for Adenosine Regulation (G2542)

Target Name: SLC37A4

NCBI ID: G2542

SLC37A4

SLC37A4: A Potential Drug Target for Adenosine Regulation

SLC37A4 (SLC37A4 variant 4) is a protein that is expressed in various tissues of the body, including the brain, heart, and liver. It is a member of the SLC family of transmembrane proteins, which are involved in the transport of various substances across the cell membrane. One of the unique features of SLC37A4 is its role in the regulation of the levels of a hormone called adenosine in the body.

In recent years, researchers have become increasingly interested in SLC37A4 as a potential drug target or biomarker. This is because the levels of adenosine in the body have been shown to play a role in a number of important physiological processes, including memory, emotion, and pain signaling. Additionally, SLC37A4 has been shown to be involved in the regulation of various signaling pathways in the body, which could make it an attractive target for drug development.

One of the potential benefits of targeting SLC37A4 is its ability to modulate the levels of adenosine in the body. Adenosine is a naturally occurring compound that is produced by the body in response to stress, inflammation, or other stimuli. It is important for maintaining homeostasis in the body by regulation of various physiological processes, including blood pressure, heart rate, and inflammation. However, too much adenosine can be harmful, and it is thought to contribute to a number of diseases, including heart failure, cancer, and neurodegenerative disorders.

SLC37A4 has been shown to play a role in regulating the levels of adenosine in the body by modulating the activity of a protein called adenosine receptor 70 (AR70). AR70 is a G protein-coupled receptor that is expressed in various tissues of the body, including the brain, heart, and liver. It is involved in the regulation of various physiological processes, including pain signaling, inflammation, and blood pressure. SLC37A4 has been shown to interact with AR70 and modulate its activity, which could potentially lead to the regulation of adenosine levels in the body.

Another potential benefit of targeting SLC37A4 is its involvement in the regulation of signaling pathways in the body. SLC37A4 has been shown to be involved in the regulation of various signaling pathways, including the TGF-β pathway and the NF-kappa-B pathway. These pathways are involved in the regulation of various physiological processes, including cell growth, differentiation, and inflammation. Targeting SLC37A4 with drugs that can modulate its activity could potentially lead to the regulation of these signaling pathways and the prevention of various diseases.

In conclusion, SLC37A4 is a protein that has been shown to play a role in the regulation of various physiological processes in the body. Its unique role in the regulation of adenosine levels and its involvement in the regulation of signaling pathways make it an attractive target for drug development. Further research is needed to fully understand the mechanisms of SLC37A4 and its potential as a drug target or biomarker.

Protein Name: Solute Carrier Family 37 Member 4

Functions: Inorganic phosphate and glucose-6-phosphate antiporter of the endoplasmic reticulum. Transports cytoplasmic glucose-6-phosphate into the lumen of the endoplasmic reticulum and translocates inorganic phosphate into the opposite direction (PubMed:33964207). Forms with glucose-6-phosphatase the complex responsible for glucose production through glycogenolysis and gluconeogenesis. Hence, it plays a central role in homeostatic regulation of blood glucose levels

The "SLC37A4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC37A4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets